Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group. Fosså SD, et al. Among authors: de wit r, de prijck l, de mulder ph. Br J Cancer. 2005 Nov 28;93(11):1209-14. doi: 10.1038/sj.bjc.6602830. Br J Cancer. 2005. PMID: 16251877 Free PMC article. Clinical Trial.
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
de Wit R, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW, Spaander PJ, de Pauw M, Sylvester R. de Wit R, et al. Among authors: de pauw m, de mulder ph. Br J Cancer. 1995 Jun;71(6):1311-4. doi: 10.1038/bjc.1995.254. Br J Cancer. 1995. PMID: 7540039 Free PMC article. Clinical Trial.
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. de Wit R, et al. Among authors: de mulder ph. Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71. Br J Cancer. 1997. PMID: 9020492 Free PMC article. Clinical Trial.
Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
van Oosterom AT, Stoter G, Bono AV, Splinter TA, Fossa SD, Verbaeys AJ, de Mulder PH, de Pauw M, Sylvester R. van Oosterom AT, et al. Among authors: de pauw m, de mulder ph. Eur J Cancer Clin Oncol. 1989 Aug;25(8):1249-50. doi: 10.1016/0277-5379(89)90422-7. Eur J Cancer Clin Oncol. 1989. PMID: 2767112 No abstract available.
Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Aass N, et al. Among authors: de prijck l, de mulder ph. J Clin Oncol. 2005 Jun 20;23(18):4172-8. doi: 10.1200/JCO.2005.07.114. J Clin Oncol. 2005. PMID: 15961764 Clinical Trial.
211 results